Filing identity and reporting period
Important identity mismatch: The supplied filing is Athira Pharma, Inc.’s Form 10-Q, not Leonabio, Inc.’s. It covers the quarter ended March 31, 2024, and was signed May 15, 2024. The summary below describes Athira Pharma.
Business context and outlook
Athira is a clinical-stage biopharmaceutical company developing small molecules for neurological disorders. Its lead candidate, fosgonimeton, is being studied for Alzheimer’s disease (AD); the company has no approved products and has not generated product revenue.
LIFT-AD, a Phase 2/3 trial in mild-to-moderate AD, completed enrollment at approximately 315 patients in January 2024. The trial focuses on patients not taking background acetylcholinesterase inhibitors and on a 40 mg dose. Management expected topline results in the second half of 2024. The ACT-AD trial’s primary and secondary endpoints were not met under the planned analyses; favorable subgroup findings were post hoc and not statistically significant. The company says cash, cash equivalents and investments should fund operations and capital expenditures for at least 12 months following the filing date, but expects to need additional capital.
Financial performance and liquidity
Amounts below are in millions of dollars except per-share data. Athira reported no product revenue in either comparison period.
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Research and development expense | $21.2 | $21.3 |
| General and administrative expense | $6.5 | $8.5 |
| Total operating expenses | $27.7 | $29.8 |
| Operating loss | $(27.7) | $(29.8) |
| Net loss | $(26.3) | $(27.8) |
| Net loss per share, basic and diluted | $(0.69) | $(0.73) |
| Operating cash flow | $(25.8) | $(26.2) |
| Cash, cash equivalents and investments at period-end | $122.1 | Not stated here for comparison |
Net loss improved by $1.5 million year over year, principally alongside lower G&A expense; R&D expense was essentially flat. G&A declined $2.0 million, including lower legal, business development and professional services costs. Other income was $1.4 million, down from $1.8 million, and Q1 2024 included no grant income. No operating margin is meaningful given the absence of revenue.
At March 31, 2024, cash and cash equivalents were $77.8 million and short-term investments were $44.3 million, compared with $90.6 million and $56.8 million, respectively, at December 31, 2023. Total assets were $133.5 million; total liabilities were $26.7 million, including $25.6 million current liabilities; stockholders’ equity was $106.7 million. The filing reports no debt balance. Cash, cash equivalents and restricted cash decreased $12.8 million during the quarter. Investing activities provided $13.0 million, mainly from investment maturities, and financing activities provided no cash.
Material developments, risks and unusual items
- Clinical risk: Fosgonimeton’s prior AD and Parkinson’s disease dementia/dementia with Lewy bodies studies had endpoints that were not met under planned analyses. LIFT-AD results remain a key catalyst, and success is uncertain.
- Research-integrity and intellectual-property risk: A board special committee found that former CEO Leen Kawas altered images in her doctoral dissertation and at least four co-authored papers; it also found challenged papers were cited in certain company communications and applications, and that WSU’s exclusively licensed dihexa patent incorporated certain altered images. The company warns of potential effects on reputation, grants and licensed intellectual property. The DOJ’s Civil Investigative Demand concerning WSU and NIH matters remained unresolved in the filing.
- Legal proceedings: A proposed $10.0 million securities class-action settlement had preliminary court approval, with final approval hearing set for October 25, 2024. The company recorded a $10.0 million settlement liability and a separate $1.6 million insurance recovery receivable. A derivative-action settlement involving governance reforms and plaintiffs’ counsel fees received preliminary approval on May 3, 2024, after quarter-end. The SEC notified the company on March 29, 2024 that its investigation concluded without enforcement action against Athira.
- Funding and dilution: The company has an unused at-the-market equity facility of up to $75.0 million and may pursue equity, debt, collaboration or licensing funding. Additional capital may dilute shareholders or require concessions; management could also delay or reduce programs to conserve cash.
- Equity overhang: At March 31, 2024, 10.2 million stock options were outstanding, alongside other reserved or available shares. This may dilute existing holders if issued or exercised.
- Other commitments: Operating lease payments totaled $1.7 million undiscounted, including $0.5 million due within 12 months. Up to $0.9 million of WSU milestone payments may become due upon specified future events.
- Controls: Management concluded disclosure controls were effective at the reasonable-assurance level, with no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Confirm the intended issuer: this filing is for Athira Pharma (Nasdaq: ATHA), not Leonabio.
- Check final LIFT-AD results against the company’s second-half 2024 expected timing, and assess the prespecified population, endpoints and statistical significance.
- Track the DOJ demand and WSU review, including any consequences for grants, the dihexa license or related patents.
- Verify final court approval and payment terms for the securities and derivative settlements, including insurance recovery.
- Monitor cash burn, runway assumptions, financing activity under the $75.0 million ATM facility and potential share dilution.